Beta amyloid peptide N-terminal

Human beta amyloid peptide 45

This antibody recognizes the N-terminal peptide (DAEFRHDS) of human beta amyloid peptides and also reacts with full length Abeta40, Abeta42 and Abeta43.

Human

Abeta40, Abeta42 and Abeta43 are different only at the few C-end amino acids. While the C-end amino acids showed no species-specificity in mammalians, the N-terminal amino acid sequences have minor discrepancies between difference species.
Amyloid beta peptides Abeta42 and Abeta40 have been investigated extensively for predicating Alzheimer’s disease. A recent study on A Abeta43 in brain showed that Abeta43 is more fibrillogenic than the other amyloid beta peptides and may be useful as a biomarker or therapeutic target for Alzheimer’s disease. Antibody to N-terminal sequence can bind to all the three amyloid beta peptides.

Double distilled water is recommended to adjust the final concentration to 1.00 mg/mL.

Aging and neurodegenerative diseases